Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463149 | 0.83 | LMNA (0.50) | MAPTALDH1A1ALOX15HSD17B10PSMD14 | |
| SCHEMBL5820913 | 0.75 | POLB (0.42) | MAPTALDH1A1ALOX15HSD17B10HPGD | |
| SCHEMBL5821360 | 0.74 | ALDH1A1 (0.49) | MAPTALDH1A1ALOX15HSD17B10PSMD14 | |
| SCHEMBL3982930 | 0.73 | MAPT (0.52) | MAPTALDH1A1HSD17B10LMNACCNB2 | |
| SCHEMBL4414573 | 0.73 | ALDH1A1 (0.50) | MAPTALDH1A1ALOX15HSD17B10PSMD14 | |
| SCHEMBL4264795 | 0.73 | NAPRT (0.54) | MAPTALDH1A1ALOX15HSD17B10PSMD14 | |
| SCHEMBL9830883 | 0.72 | KMT2A (0.44) | ALDH1A1HSD17B10LMNACDK2KMT2A | |
| SCHEMBL5811173 | 0.72 | ALDH1A1 (0.50) | MAPTALDH1A1HSD17B10LMNAHTT | |
| SCHEMBL1318409 | 0.72 | ALDH1A1 (0.49) | MAPTALDH1A1ALOX15HSD17B10PSMD14 | |
| SCHEMBL8192196 | 0.72 | MAPT (0.42) | MAPTALDH1A1ALOX15HSD17B10PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102675320-A | Process for synthesizing indiplon serving as sedative hypnotic medicine suitable for industrial production | INST PHARM & TOXICOLOGY AMMS | 2012-09-19 | — | — | CN | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| CN-1906197-A | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2007-01-31 | — | — | CN | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| EP-0129846-B1 | (3-AMINO-1H-PYRAZOL-4-YL)(ARYL)METHANONES | AMERICAN CYANAMID COMPANY (US) | 1991-05-08 | — | — | EP | claimed |
| US-4980472-A | REACTING ACETONITRILE DERIVATIVE WITH AMINOGUANIDINE DERIVATIVE | AMERICAN CYANAMID COMPANY (US) | 1990-12-25 | — | — | US | claimed |
| US-4900836-A | (3-amino-1H-pyrazol-4-yl) (aryl)methanones | AMERICAN CYANAMID COMPANY (US) | 1990-02-13 | — | — | US | claimed |
| EP-0129846-A2 | (3-Amino-1H-pyrazol-4-yl)(aryl)methanones | AMERICAN CYANAMID COMPANY (US) | 1985-01-02 | — | — | EP | claimed |
| CN-102174048-B | Novel polymorphic form beta of soporifics | INST RADIATION MED AMMS PLA | 2014-09-17 | — | — | CN | disclosed |
| CN-102180879-B | Polycrystalline type alpha acetic acid solvate of hypnotic | INST RADIATION MED AMMS PLA | 2013-05-01 | — | — | CN | disclosed |
| CN-102675320-A | Process for synthesizing indiplon serving as sedative hypnotic medicine suitable for industrial production | INST PHARM & TOXICOLOGY AMMS | 2012-09-19 | — | — | CN | disclosed |
| CN-101870700-B | Method for synthesizing Indiplon | UNIV PLA 3RD MILITARY MEDICAL | 2012-05-23 | — | — | CN | disclosed |
| US-6399621-B1 | SEDATIVE, HYPNOTIC, ANXIOLYTIC, ANTICONVULSANT, AND SKELETAL MUSCLE RELAXANT AGENT | AMERICAN CYANAMID COMPANY | 2002-06-04 | — | — | US | disclosed |
| EP-1206248-A2 | CONTROLLED-RELEASE SEDATIVE-HYPNOTIC COMPOSITIONS AND METHODS RELATED THERETO | Neurocrine Biosciences, Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6384221-B1 | RECRYSTALLIZATION PURIFICATION | NEUROCRINE BIOSCIENCES, INC. | 2002-05-07 | — | — | US | disclosed |
| WO-2001015700-A1 | POLYMORPHS OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]-PYRIMIDIN -7-YL }PHENYL )ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001013895-A2 | CONTROLLED-RELEASE SEDATIVE-HYPNOTIC COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | MAPT 1611/4885ALDH1A1 1128/4885ALOX15 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.